Emerging Therapies for Inflammatory Bowel Disease

POSTERS OF DISTINCTION P–001 to P–018

(2018)   AMERICAN JOURNAL OF GASTROENTEROLOGY

Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease

(2018) Britt Christensen et al.   Clinical Gastroenterology and Hepatology

OP006 Apremilast for active ulcerative colitis: a phase 2, randomised, double-blind, placebo-controlled induction study

(2018) S Danese et al.   Journal of Crohns & Colitis

Etrolizumab Treatment Improves Histological Activity as Assessed by the Robarts Histopathology Index

(2017) Brian G. Feagan et al.   GASTROENTEROLOGY

Efficacy and Safety of Abrilumab in Subjects with Moderate to Severe Ulcerative Colitis: Results of a Phase 2B, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study

(2017) William J. Sandborn et al.   GASTROENTEROLOGY

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials

(2017) Julian Panés et al.   GUT

Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis

(2017) Robert Wolk et al.   Journal of Clinical Lipidology

Faecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis

(2017) Sudarshan Paramsothy et al.   Journal of Crohns & Colitis

Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial

(2017) Séverine Vermeire et al.   LANCET

Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial

(2017) Sudarshan Paramsothy et al.   LANCET

Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial

(2017) Séverine Vermeire et al.   LANCET

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

(2017) Brian G Feagan et al.   LANCET

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

(2017) Kristin K Jørgensen et al.   LANCET

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

(2017) Kim A. Papp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

(2017) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib improves atherosclerosis despite up-regulating serum cholesterol in patients with active rheumatoid arthritis: a cohort study

(2017) Kensuke Kume et al.   RHEUMATOLOGY INTERNATIONAL

Novel Targeted Therapies for Inflammatory Bowel Disease

(2017) Mehmet Coskun et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)

(2016) A Kavanaugh et al.   ANNALS OF THE RHEUMATIC DISEASES

Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)

(2016) R Westhovens et al.   ANNALS OF THE RHEUMATIC DISEASES

Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity

(2016) F L Scott et al.   BRITISH JOURNAL OF PHARMACOLOGY

Clinical pharmacology, efficacy, and safety aspects of sphingosine-1-phosphate receptor modulators

(2016) Pierre-Eric Juif et al.   Expert Opinion on Drug Metabolism & Toxicology

Mo1778 The Toll-Like-Receptor 9 Agonist DIMS0150 Demonstrates Therapeutic Efficacy for the Patient Reported Outcome Measures PRO-2 and Clinpro in Moderate to Severe Active Ulcerative Colitis

(2016) Raja Atreya et al.   GASTROENTEROLOGY

Patients with Refractory Crohnʼs Disease Successfully Treated with Ustekinumab

(2016) Kimberly A. Harris et al.   INFLAMMATORY BOWEL DISEASES

Effects of AVX-470, an Oral, Locally Acting Anti-Tumour Necrosis Factor Antibody, on Tissue Biomarkers in Patients with Active Ulcerative Colitis

(2016) Deborah S. Hartman et al.   Journal of Crohns & Colitis

AVX-470, an Orally Delivered Anti-Tumour Necrosis Factor Antibody for Treatment of Active Ulcerative Colitis: Results of a First-in-Human Trial

(2016) M. Scott Harris et al.   Journal of Crohns & Colitis

Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis

(2016) Raja Atreya et al.   Journal of Crohns & Colitis

Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study

(2016) Lisa J. T. Smits et al.   Journal of Crohns & Colitis

Sphingosine-1-phosphate receptor-1 (S1P1) is expressed by lymphocytes, dendritic cells and endothelium and modulated during inflammatory bowel disease

(2016) T Karuppuchamy et al.   Mucosal Immunology

Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis

(2016) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

(2016) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis

(2015) David T. Rubin et al.   DIGESTIVE DISEASES AND SCIENCES

Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis

(2015) Gary R. Lichtenstein et al.   Journal of Crohns & Colitis

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

(2015) Kim Papp et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn’s Disease

(2015) Giovanni Monteleone et al.   NEW ENGLAND JOURNAL OF MEDICINE

First Multicenter Study of Modified Release Phosphatidylcholine “LT-02” in Ulcerative Colitis: A Randomized, Placebo-Controlled Trial in Mesalazine-Refractory Courses

(2014) Max Karner et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Biomarkers can predict potential clinical responders to DIMS0150 a toll-like receptor 9 agonist in ulcerative colitis patients

(2014) Nikolai V Kuznetsov et al.   BMC GASTROENTEROLOGY

Clinical pharmacology of AMG 181, a gut-specific human anti-α4β7monoclonal antibody, for treating inflammatory bowel diseases

(2014) Wei-Jian Pan et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Preclinical development of AMG 139, a human antibody specifically targeting IL-23

(2014) K Köck et al.   BRITISH JOURNAL OF PHARMACOLOGY

Complications and surgery in the inflammatory bowel diseases biological era

(2014) Harry Sokol et al.   CURRENT OPINION IN GASTROENTEROLOGY

Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies

(2014) J. Wollenhaupt et al.   JOURNAL OF RHEUMATOLOGY

Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial

(2014) Séverine Vermeire et al.   LANCET

Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study

(2013) Simon P L Travis et al.   GUT

Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment

(2013) Cornelia Tillack et al.   GUT

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2013) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

(2013) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis

(2012) Paul J Rutgeerts et al.   GUT

Topical Treatment with the Toll-like Receptor Agonist DIMS0150 Has Potential for Lasting Relief of Symptoms in Patients with Chronic Active Ulcerative Colitis by Restoring Glucocorticoid Sensitivity

(2012) Eugen Musch et al.   INFLAMMATORY BOWEL DISEASES

Phase I Clinical Trial of Smad7 Knockdown Using Antisense Oligonucleotide in Patients With Active Crohn's Disease

(2012) Giovanni Monteleone et al.   MOLECULAR THERAPY

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

(2012) Roy Fleischmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

(2012) Ronald F. van Vollenhoven et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Proinflammatory Cytokines in the Pathogenesis of Inflammatory Bowel Diseases

(2011) Warren Strober et al.   GASTROENTEROLOGY

The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study

(2011) S. Vermeire et al.   GUT

Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection

(2010) Mark E. Flanagan et al.   JOURNAL OF MEDICINAL CHEMISTRY

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease

(2008) William J. Sandborn et al.   GASTROENTEROLOGY

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

ORAL PHOSPHATIDYLCHOLINE PRESERVES THE GASTROINTESTINAL MUCOSAL BARRIER DURING LPS-INDUCED INFLAMMATION

(2008) Elizabeth J. Dial et al.   SHOCK